Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2010-8-9
pubmed:abstractText
This report summarizes the first phase 1 trial treating patients with microalbuminuric diabetic kidney disease (DKD) using FG-3019, a human monoclonal antibody to connective tissue growth factor (CTGF). CTGF is critically involved in processes of progressive fibrosis, including DKD. This phase 1, open-label, dose-escalation trial evaluated safety, pharmacokinetics, and possible therapeutic effects of FG-3019 on albuminuria, proteinuria, and tubular proteins.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-10075613, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-11135082, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-11278731, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-11565517, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-11737607, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-11744618, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-12087577, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-12110001, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-12114504, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-12134160, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-12819040, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-12941731, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-14583661, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-14633859, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-14747372, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-15111539, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-15153554, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-15546890, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-15727802, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-15882275, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-15950619, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-15976312, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-15980944, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-16272194, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-16373901, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-16380465, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-16408108, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-16531982, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-16723984, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-16856934, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-16914537, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-17554073, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-18075496, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-18319310, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-18344285, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-18632843, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-19409809, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-8374172, http://linkedlifedata.com/resource/pubmed/commentcorrection/20522536-9551391
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1555-905X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1420-8
pubmed:dateRevised
2011-8-9
pubmed:meshHeading
pubmed-meshheading:20522536-Adult, pubmed-meshheading:20522536-Aged, pubmed-meshheading:20522536-Albuminuria, pubmed-meshheading:20522536-Antibodies, Monoclonal, pubmed-meshheading:20522536-Connective Tissue Growth Factor, pubmed-meshheading:20522536-Diabetes Mellitus, Type 1, pubmed-meshheading:20522536-Diabetes Mellitus, Type 2, pubmed-meshheading:20522536-Diabetic Nephropathies, pubmed-meshheading:20522536-Drug Administration Schedule, pubmed-meshheading:20522536-Female, pubmed-meshheading:20522536-Glomerular Filtration Rate, pubmed-meshheading:20522536-Humans, pubmed-meshheading:20522536-Hypoglycemic Agents, pubmed-meshheading:20522536-Infusions, Intravenous, pubmed-meshheading:20522536-Kidney Tubules, pubmed-meshheading:20522536-Male, pubmed-meshheading:20522536-Middle Aged, pubmed-meshheading:20522536-Treatment Outcome
pubmed:year
2010
pubmed:articleTitle
Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria.
pubmed:affiliation
Division of Nephrology and Hypertension, Los Angeles BioMedical Research Institute, Torrance, California 90502, USA. sadler@labiomed.org
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I